deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01989546

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

Sponsor: National Cancer Institute (NCI)

Conditions Advanced Breast Cancer Advanced Ovarian Cancer Advanced Solid Tumors Primary Peritoneal Cancer
Interventions BMN 673
Updated 18 times since 2017 Last updated: Feb 2, 2021 Started: Feb 4, 2014 Primary completion: Mar 26, 2020 Completion: Mar 26, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Advanced Breast Cancer and Advanced Ovarian Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 18 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Dec 2017 · 5 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Jun 2019 · 10 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Oct 2019 · 3 months · monthly snapshot~Oct 2019 – ~Apr 2020 · 6 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Oct 2020 · 5 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Jul 2024 · 40 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Mar 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Feb 2021 — Mar 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 13 earlier versions

  1. Oct 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  2. May 2020 — Oct 2020 [monthly]

    Completed PHASE1_PHASE2

  3. Apr 2020 — May 2020 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  4. Oct 2019 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jul 2019 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Aug 2018 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Completed → Recruiting

  11. Jul 2017 — Dec 2017 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  12. Feb 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  13. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations